LH · Q1 2026 Earnings

Cautious

Labcorp

Reported April 30, 2026

30-second summary

Q1 FY2026 revenue grew 5.8% YoY to $3.54B and non-GAAP EPS came in at $4.25, with management raising the FY2026 EPS midpoint $0.13 to $18.03 and lifting both segment revenue ranges — Biopharma's low end moved meaningfully (+80bps to 3.8%). The headline is bullish on guidance, but Diagnostics organic growth printed 2.9% — below Q4 FY2025's already-soft 4.1% and well below the 4.5% watch-list threshold — and Biopharma TTM book-to-bill fell to 1.04 from 1.09, the third consecutive sub-1.10 print. Management is funding the EPS raise on margin and BLS momentum, not on Diagnostics volume recovery, and the volume-acceleration thesis that anchored 2025 looks structurally broken — adj. operating margin expanded only 30bps YoY at the enterprise level, consistent with the press release and prepared remarks.

Headline numbers

EPS

Q1 FY2026

$4.25

Revenue

Q1 FY2026

$3.54B

+5.8% YoY

Gross margin

Q1 FY2026

28.7%

Free cash flow

Q1 FY2026

$0.07B

Operating margin

Q1 FY2026

10.8%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$3.54B	+5.8%	$3.52B	+0.6%
EPS	$4.25	—	$4.07	+4.4%
Gross margin	28.7%	—	28.2%	+50bps
Operating margin	10.8%	—	7.6%	+320bps
Free cash flow	$0.07B	—	$0.49B	-85.6%

Guidance

Company raised FY2026 Adjusted EPS guidance to $18.03 midpoint (+$0.13) and lifted revenue/segment growth ranges, signaling confidence in organic momentum and margin expansion ahead.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY 2026	$14.61B to $14.79B	$14.65B to $14.80B	+$0.04B to +$0.01B at midpoint; midpoint raised from $14.70B to $14.725B	Raised
Adjusted EPS	FY 2026	$17.55 to $18.25 (midpoint $17.90)	$17.70 to $18.35 (midpoint $18.025)	+$0.15 to +$0.10 range; midpoint raised +$0.125	Raised
Enterprise Revenue Growth	FY 2026	4.7% to 6.0%	5.0% to 6.1%	+0.3 to +0.1 percentage points	Raised
Diagnostics Laboratories Revenue Growth	FY 2026	5.0% to 6.0%	5.1% to 5.9%	+0.1 to -0.1 percentage points; midpoint narrowed but held near prior range	Raised
Biopharma Laboratory Services Revenue Growth	FY 2026	3.0% to 5.0%	3.8% to 5.4%	+0.8 to +0.4 percentage points; midpoint raised from 4.0% to 4.6%	Raised

Reaffirmed unchanged this quarter: Free Cash Flow ($1.24 billion to $1.36 billion)

Segment KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
Diagnostics Laboratories	$2.76B	+5.0%
Biopharma Laboratory Services	$0.781B	+8.2%

Other KPIs

Q1 FY2026

Segment	Q1 FY2026
Adjusted Operating Margin	14.4%
Diagnostics Laboratories Adjusted Operating Margin	16.6%
Biopharma Laboratory Services Adjusted Operating Margin	15.5%
Organic Revenue Growth	3.1%
Diagnostics Organic Growth	2.9%
Biopharma Organic Growth	3.7%
TTM Backlog	$8.64 billion
Book to Bill Ratio	1.04

Management tone

Organic volume re-acceleration → navigating FX and PAMA headwinds → operational candor and strategic rebuild → confidence on margin while volume softens further.

Three quarters ago specialty testing was the platform pull-through engine driving the 3.5% organic volume re-acceleration. Two quarters ago that thesis was already under pressure as organic dropped to 4.1%. This quarter, with Diagnostics organic at 2.9% and total organic at 3.1%, management's framing has pivoted to specialty growing "2-3x faster than the broader market" — a relative metric that survives a slowing broader market. The shift from absolute volume acceleration to relative outperformance is the tell: when the absolute number stops cooperating, the narrative migrates to ratio language. The release frames it as "When providers choose LabCorp for specialty testing, we see them consolidating a greater share of their patients' testing needs with LabCorp," which is the same wallet-share argument from Q3 FY2025 — but now defending against a 2.9% organic print rather than amplifying a 6.3% one.

Two quarters ago the PAMA legislative delay through year-end 2026 removed the immediate hit and contingent savings were held in reserve. This quarter the framing crystallized into pushing for the Results Act as the permanent fix while continuing to comply with PAMA data submission. That posture — pressing for the long-term legislative solution while acknowledging the FY2027 PAMA cut depends on how many other labs report — is the most assertive tone shift in this print. The implicit consolidation thesis (that LabCorp benefits if smaller labs come under pressure) is unproven and depends on execution Labcorp has not yet demonstrated under weakening organic volume.

Last quarter's narrative on weather was passive ("Q4 organic would have been over 2% adjusted"). This quarter the prepared remarks quantified weather impact at $15M and explicitly stated that organic volume growth would have been closer to 2% absent weather. The shift from passive to quantified is a credibility move — but it also signals management knows the volume story needs more proof points, not fewer.

Last quarter the early development restructuring was characterized as a sunk-cost acknowledgment. This quarter management committed to a clean timeline ("strategic actions in ED winding down by end of Q2") and explicitly framed the central lab as the BLS growth engine — "mid single digits on an organic constant currency basis." That's tighter operational guidance than Q4 FY2025's broader strategic framing, and it provides a clear Q2 milestone against which the ED restructuring will be judged.

The most notable phrase from the prepared remarks: "I feel good about the momentum. It enabled us to raise the midpoint of the guidance for our BLS segment." Management is explicitly attributing the BLS guidance raise to forward visibility, not catch-up. Investors should mark that against the 1.04 book-to-bill — the two signals are in tension.

Recurring themes management leaned on this quarter:

Specialty diagnostics growth (oncology, neurology, women's health, autoimmune) expanding 2-3x faster than broader marketAI and digital pathology deployment accelerating operational efficiency and customer experienceM&A pipeline strength supporting inorganic growth alongside organic growthCentral labs outperforming early development; strategic actions in ED winding down by end of Q2Consumer health (OnDemand) maintaining double-digit growth; My LabCorp app launching May with AI assistantMargin expansion across both segments driven by organic growth, mix shift to specialty testing, and Launchpad initiatives

Risks management surfaced:

ACA enrollment premium payment and testing utilization uncertainty (estimated 30 bps impact embedded in guidance)PAMA implementation in January causing near-term volume/pricing pressure before long-term M&A pipeline benefitsWeather impacts (estimated $15M in Q1; fuel costs estimated $5-10M for full year)Specialty testing reimbursement not yet optimal despite strong volume growthEarly development business strategic actions creating temporary revenue headwind through Q2

Answers to last quarter's watch list

Q1 FY2026 Diagnostics organic growth — needs to rebound above 4.5% — Diagnostics organic growth printed 2.9%, well below the 4.5% threshold and weaker than Q4 FY2025's already-soft 4.1%. Management quantified weather as a $15M enterprise drag and indicated organic volume would have been closer to 2% absent weather. The volume-acceleration thesis that anchored Q2-Q3 FY2025 is structurally broken — three consecutive prints of deteriorating organic growth (6.3% → 4.1% → 2.9%) is now a trend, not a fluke.

Resolved negatively

Biopharma TTM book-to-bill — third consecutive print below 1.10 — TTM book-to-bill came in at 1.04, the third straight quarter below 1.10 and a five-tick deterioration from Q3/Q4 FY2025's 1.09. Management framed the quarterly 0.94 as timing-driven and guided to sequential improvement in Q2 FY2026, but the TTM trend is now a clear pattern. BLS revenue growth of 8.2% YoY and the segment guide raise (floor +80bps) are real positives, but the leading indicator is saying the recovery is structurally capped.

Resolved negatively

Early development $50M divestiture/consolidation completion and margin impact — Management committed to ED strategic actions winding down by end of Q2 FY2026, on the prior timeline. BLS adj. operating margin came in at 15.5%, up 60bps YoY driven by Central Labs, though down from Q4 FY2025's 17.2% on seasonal mix and restructuring. The cleaner read will come in Q2 FY2026 when the actions are complete.

Continue monitoring

FY2026 capex run-rate vs the 4%-of-revenue framing — Q1 FY2026 FCF of $70.5M is the seasonally weak quarter; FY FCF guide was reaffirmed at $1.24B–$1.36B, suggesting capex pacing is on track with the 4%-of-revenue framing. Management did not telegraph incremental facility investment beyond the disclosed central lab build. Not enough data points yet to assess vs the full-year run-rate.

Continue monitoring

Consumer business or Invitae/specialty breakout — Management again declined to break out consumer or specialty as separate revenue lines. The release notes consumer health (OnDemand) maintaining double-digit growth and a My LabCorp app launching May with an AI assistant, but no revenue contribution figure. Specialty growth is described qualitatively as "2-3x faster than the broader market" — a relative metric, not a dollar disclosure. The disclosure surface has not widened.

Not resolved

What to watch into next quarter

Q2 FY2026 Diagnostics organic growth — needs to recover meaningfully above 3.5%, or the volume thesis is dead. Q1 FY2026's 2.9% print after Q4 FY2025's 4.1% is now a clear deceleration trend. If Q2 FY2026 prints another sub-3.5% organic read, FY guidance is at risk despite this quarter's raise, and the long-running specialty-testing volume narrative becomes uninvestable.

BLS adj. operating margin post-ED restructuring. Management committed to ED strategic actions winding down by end of Q2 FY2026. Watch whether BLS margin recovers from Q1 FY2026's 15.5% back toward Q4 FY2025's 17.2% — if it doesn't expand by Q3 FY2026, the restructuring math was lower-quality than advertised.

Biopharma TTM book-to-bill — fourth consecutive sub-1.10 print would force a structural reset on BLS. A move further below 1.04 would be a true alarm; even a recovery to 1.06-1.08 would not invalidate the structural-cap concern.

PAMA / Results Act resolution. Management is pushing for the Results Act as the permanent fix while continuing PAMA data submission. Watch for CBO score, CMS technical assessment, and the count of reporting labs — all three shape the FY2027 reimbursement setup.

Free cash flow conversion in Q2 FY2026. With capex elevated at ~4% of revenue and FY FCF guide reaffirmed at $1.24B–$1.36B, Q2 FY2026 needs to ramp materially from Q1 FY2026's $70.5M to keep the year on track. A second weak FCF quarter would force a guide cut later in the year.

Sources

Labcorp Q1 FY2026 Form 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/920148/000092014826000135/form8-kexhibit9911q26.htm
Labcorp Q4 FY2025 brief (Tapebrief internal — prior coverage)
Labcorp Q3 FY2025 brief (Tapebrief internal — prior coverage)
Labcorp Q2 FY2025 brief (Tapebrief internal — prior coverage)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.